BioLineRx Receives Orphan Drug Designation From the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic Cancer

Go back to BioLineRx Receives Orphan Drug Designation From the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic Cancer
Bioline RX Ltd Ordinary shares (AMEX: BLNEF) Delayed: 0.86 --0 (-0%)
Previous Close $0.86    52 Week High $1.54 
Open $1.64    52 Week Low $1.15 
Day High $0.86    P/E N/A 
Day Low $0.86    EPS $0.00 
Volume 1,500       

BIOLINE RX SP ADR (NASDAQ: BLRX) Delayed: 2.49 -0.04 (1.58%)
Previous Close $2.53    52 Week High $1.63 
Open $2.50    52 Week Low $0.71 
Day High $2.51    P/E N/A 
Day Low $2.44    EPS $0.00 
Volume 2,752       

BIOLINE RX SP ADR (NASDAQ: BLRX) Delayed: 2.49 -0.04 (1.58%)
Previous Close $2.53    52 Week High $1.63 
Open $2.50    52 Week Low $0.71 
Day High $2.51    P/E N/A 
Day Low $2.44    EPS $0.00 
Volume 2,752       

BIOLINE RX SP ADR (NASDAQ: BLRX) Delayed: 2.49 -0.04 (1.58%)
Previous Close $2.53    52 Week High $1.63 
Open $2.50    52 Week Low $0.71 
Day High $2.51    P/E N/A 
Day Low $2.44    EPS $0.00 
Volume 2,752